Store-operated calcium entry into rat basophil leukaemia cells: contribution of TRPC3 and Orai1 by Schleifer, Hannes et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open Access Meeting abstract
Store-operated calcium entry into rat basophil leukaemia cells: 
contribution of TRPC3 and Orai1
Hannes Schleifer1, Michael Poteser1, C Oliver Kappe2, Christoph Romanin3 
and Klaus Groschner*1
Address: 1Institute for Pharmaceutical Sciences, Pharmacology and Toxicology, Karl Franzens University of Graz, 8010 Graz, Austria, 2Institute of 
Chemistry, Karl Franzens University of Graz, 8010 Graz, Austria and 3Institute for Biophyics, Johannes Kepler University, 4040 Linz, Austria
Email: Klaus Groschner* - klaus.groschner@uni-graz.at
* Corresponding author    
Background
Before the discovery of STIM and Orai proteins, mamma-
lian TRPC channels, including TRPC3, were considered as
candidates for mediating store-operated Ca2+  entry
(SOCE). This calcium entry pathway governs diverse cel-
lular processes from exocytosis, cellular remodelling to
gene transcription. Although a prominent role of Orai1 is
now well established for immune cells, the role of TRPC
proteins and the possible crosstalk between these two ion
channels families to the overall store operated calcium
entry into cells of the immune system is still elusive.
Results
Calcium imaging experiments with Fura2-AM-loaded rat
basophil leukaemia (RBL) cells overexpressing either
TRPC3, Orai1 or dominant negative mutants of these
channel proteins sustain evidence for a complex interac-
tion network between TRPC and Orai pathways. Overex-
pression of either wild-type protein (TRPC3 or Orai1)
resulted in promotion of calcium entry as compared to
controls. PYR3, a novel inhibitor of NFAT activation,
which has recently been demonstrated as a selective inhib-
itor of TRPC3 channels [1], also suppressed thapsigargin-
induced calcium entry into RBL cells, being most efficient
in TRPC3-overexpressing cells. Expression of dominant
negative mutations of either channels reduced SOCE to
levels significant below controls, revealing a PYR3-resist-
ant calcium entry component that was significantly larger
in dominant negative Orai1-knock-out cells.
Conclusion
These results demonstrate a combined involvement of
TRPC3 and Orai1 in SOCE of RBL cells. It remains to be
clarified if a crosstalk between these channels exists. Inves-
tigation of down-stream signalling events such as NFAT
activation and degranulation confirmed the activity of
PYR3 as an inhibitor of mast cell function. In aggregate,
our results support evidence for a complex interaction net-
work of TRPC and Orai channels in immune cells.
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